
<DOC>
<DOCNO>WT02-B15-68</DOCNO>
<DOCOLDNO>IA027-000293-B028-222</DOCOLDNO>
<DOCHDR>
http://www.bernaproducts.com:80/11_oralroute.html 206.136.243.10 19970117022244 text/html 2522
HTTP/1.0 200 OK
Date: Fri, 17 Jan 1997 05:13:53 GMT
Server: Apache/1.1.0
Content-type: text/html
Content-length: 2351
Last-modified: Tue, 01 Oct 1996 06:58:26 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>11_oralroute.html</TITLE>
   <!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN"> 
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<P ALIGN=CENTER><A HREF="image11.map"><IMG ISMAP SRC="image11.gif"
WIDTH=468 HEIGHT=94 BORDER=0 ALIGN=bottom></A></P>

<P ALIGN=CENTER><A NAME="11_oralroute.html"></A></P>

<H2 ALIGN=CENTER>The ORAL route to TYPHOID PROTECTION</H2>

<H2 ALIGN=CENTER>VIVOTIF BERNA&#129;</H2>

<H3 ALIGN=CENTER>(Typhoid Vaccine Live Oral Ty21a)</H3>

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD colstart="1">
         <P><IMG SRC="oraltract.gif" WIDTH=274 HEIGHT=364 BORDER=0
         ALIGN=middle>
      </TD><TD colstart="2">
         <P>The ability of <I>S. typhi</I> to cause disease and to
         induce a protective immune response is dependent upon the
         bacteria possessing a complete lipopolysaccharide(1,2).
         The<I> S. typhi</I> Ty21a vaccine strain, by virtue of a
         reduction in enzymes essential for lipopolysaccharide
         biosynthesis, is restricted in its ability to produce
         complete lipopolysaccharide(3,4) However,a sufficient
         quantity of complete lipopolysaccharide is synthesized to
         evoke a protective immune response.</P>
         
         <P></P>
         
         <P>VIVOTIF BERNA&#129; oral vaccine is adsorbed in the
         proximal ileum, providing typhoid protection right where
         it&#185;s needed--in the GI tract. This live oral vaccine
         mimics actual clinical exposure, stimulating local, as well
         as, systemic immunity.(5-9)
      </TD></TR>
</TABLE></P>

<H3 ALIGN=CENTER>To receive a copy of this poster, call Berna
Products </H3>
<H3 ALIGN=CENTER>Customer Service at 1-(800) 533-5899</H3>

<P></P>

<P>1. Germanier, R. Infect. Immun. 2:309-315,1970. 2. Germanier, R.
E. Furer, Infect. Immun.4:663-673,1971. 3. Germanier. R. E. Furer J.
Infect. Dis.131: 553-558,1975. 4. Germanier, R. E. Furer Develop.
Biol. Standard,43: 3-7,1983. 5. Cancellieri, V., Fara, G.M., J. Inf.
Dis. (151)3, pp482-484, 1985. 6. Tagiliabue, A., et.al., Clin Exp
Immunol 62, pp242-247, 1985. 7. D&#178;Amelio, R., et. Al., Infect
Immun 56, pp 2731-2735, 1988. 8. Kantele, A., Vaccine 8, pp 321-326,
1990. 9. Kantele, A., M&aacute;kel&aacute;, P.H., Vaccine 9, pp
423-427, 1991.</P>
</BODY>
</HTML>

</DOC>